I would be very angry with the FDA if they declined to approve provenge with 56 less deaths. Then after the final 56 deaths the p value dropped below .05 and became statistically significant. I would then strongly suport DNDN rallys against the FDA and I would support any other pharmaceudical or similiar biotech company whether I was invested in them or not. I will think about what DEW says that after the study is completed additional encouraging data will have no effect on approval. What I am saying is that I would like to explore past FDA decisions on drug approvals to see if a similar event did not change the FDAs decision. It does not seem fair. Bob